Exploring the potential of the TCR repertoire as a tumor biomarker (Review)
- Authors:
- An-Li Huang
- Yan-Zhao He
- Yong Yang
- Min Pang
- Guo-Ping Zheng
- Hai-Long Wang
-
Affiliations: Institute of Cancer Biology, Basic Medical Sciences Center, School of Basic Medicine, Shanxi Medical University, Jinzhong, Shanxi 030600, P.R. China, NHC Key Laboratory of Pneumoconiosis, Shanxi Province Key Laboratory of Respiratory Disease, Department of Pulmonary and Critical Care Medicine, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Centre for Transplant and Renal Research, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales 2145, Australia - Published online on: June 28, 2024 https://doi.org/10.3892/ol.2024.14546
- Article Number: 413
-
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Pasetto A and Lu YC: Single-cell TCR and transcriptome analysis: An indispensable tool for studying T-cell biology and cancer immunotherapy. Front Immunol. 12:6890912021. View Article : Google Scholar : PubMed/NCBI | |
|
Papadakis M, Karniadakis I, Mazonakis N, Akinosoglou K, Tsioutis C and Spernovasilis N: Immune checkpoint inhibitors and infection: What is the interplay? In Vivo. 37:2409–2420. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Kong X, Zhang J, Chen S, Wang X, Xi Q, Shen H and Zhang R: Immune checkpoint inhibitors: Breakthroughs in cancer treatment. Cancer Biol Med. j.issn.2095-3941.2024.0055. 2024.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Zhong Y, Zhang Z, Zhou K, Huang Z, Yu H, Liu L, Liu S, Yang H, Zhou J, et al: Characteristics and clinical significance of T-cell receptor repertoire in hepatocellular carcinoma. Front Immunol. 13:8472632022. View Article : Google Scholar : PubMed/NCBI | |
|
Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, et al: CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 20:2424–2432. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Charles J, Mouret S, Challende I, Leccia MT, De Fraipont F, Perez S, Plantier N, Plumas J, Manuel M, Chaperot L and Aspord C: T-cell receptor diversity as a prognostic biomarker in melanoma patients. Pigment Cell Melanoma Res. 33:612–624. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chaplin DD: Overview of the immune response. J Allergy Clin Immunol. 125 (2 Suppl 2):S3–S23. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bonilla FA and Oettgen HC: Adaptive immunity. J Allergy Clin Immunol. 125 (2 Suppl 2):S33–S40. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gielis S, Moris P, Bittremieux W, De Neuter N, Ogunjimi B, Laukens K and Meysman P: Detection of enriched T cell epitope specificity in full T cell receptor sequence repertoires. Front Immunol. 10:28202019. View Article : Google Scholar : PubMed/NCBI | |
|
Lo Presti E, Dieli F and Meraviglia S: Tumor-infiltrating γδ T lymphocytes: pathogenic role, clinical significance, and differential programing in the tumor microenvironment. Front Immunol. 5:6072014. View Article : Google Scholar : PubMed/NCBI | |
|
Roth DB: V(D)J recombination: Mechanism, errors, and fidelity. Microbiol Spectr. 2:10.1128/microbiolspec.MDNA3. 0041–2014. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Schatz DG and Ji Y: Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol. 11:251–263. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mahe E, Pugh T and Kamel-Reid S: T cell clonality assessment: Past, present and future. J Clin Pathol. 71:195–200. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rosati E, Dowds CM, Liaskou E, Henriksen EKK, Karlsen TH and Franke A: Overview of methodologies for T-cell receptor repertoire analysis. BMC Biotechnol. 17:612017. View Article : Google Scholar : PubMed/NCBI | |
|
Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI and McCluskey J: T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev Immunol. 33:169–200. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Laydon DJ, Bangham CRM and Asquith B: Estimating T-cell repertoire diversity: Limitations of classical estimators and a new approach. Philos Trans R Soc Lond B Biol Sci. 370:201402912015. View Article : Google Scholar : PubMed/NCBI | |
|
Woodsworth DJ, Castellarin M and Holt RA: Sequence analysis of T-cell repertoires in health and disease. Genome Med. 5:982013. View Article : Google Scholar : PubMed/NCBI | |
|
Pai JA and Satpathy AT: High-throughput and single-cell T cell receptor sequencing technologies. Nat Methods. 18:881–892. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Shugay M, Britanova OV, Merzlyak EM, Turchaninova MA, Mamedov IZ, Tuganbaev TR, Bolotin DA, Staroverov DB, Putintseva EV, Plevova K, et al: Towards error-free profiling of immune repertoires. Nat Methods. 11:653–655. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Zhang W, Zeng X, Zhang R, Du Y, Hong X, Cao H, Su Z, Wang C, Wu J, et al: Systematic comparative evaluation of methods for investigating the TCRβ repertoire. PLoS One. 11:e01524642016. View Article : Google Scholar : PubMed/NCBI | |
|
Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW, Parsons JM, Steen MS, LaMadrid-Herrmannsfeldt MA, Williamson DW, Livingston RJ, et al: Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun. 4:26802013. View Article : Google Scholar : PubMed/NCBI | |
|
No authors listed. Rapid amplification of 5′ complementary DNA ends (5′ RACE). Nat Methods. 2:629–630. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu YY, Machleder EM, Chenchik A, Li R and Siebert PD: Reverse transcriptase template switching: A SMART approach for full-length cDNA library construction. Biotechniques. 30:892–897. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Stewart JJ, Lee CY, Ibrahim S, Watts P, Shlomchik M, Weigert M and Litwin S: A Shannon entropy analysis of immunoglobulin and T cell receptor. Mol Immunol. 34:1067–1082. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Shannon CE: A mathematical theory of communication. Bell Syst Tech J. 27:379–423. 1948. View Article : Google Scholar | |
|
Pielou EC: The measurement of diversity in different types of biological collections. J Theor Biol. 13:131–144. 1966. View Article : Google Scholar | |
|
Cui JH, Lin KR, Yuan SH, Jin YB, Chen XP, Su XK, Jiang J, Pan YM, Mao SL, Mao XF and Luo W: TCR repertoire as a novel indicator for immune monitoring and prognosis assessment of patients with cervical cancer. Front Immunol. 9:27292018. View Article : Google Scholar : PubMed/NCBI | |
|
Pan Y, Gao J, Lin J, Ma Y, Hou Z, Lin Y, Wen S, Pan M, Lu F and Huang H: High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma. Front Endocrinol (Lausanne). 14:11815382023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Zhang B, Yang Y, Zhu J, Cheng S, Mao Y, Feng L and Xiao T: Characterization of distinct T cell receptor repertoires in tumor and distant non-tumor tissues from lung cancer patients. Genomics Proteomics Bioinformatics. 17:287–296. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Song Z, Chen X, Shi Y, Huang R, Wang W, Zhu K, Lin S, Wang M, Tian G, Yang J and Chen G: Evaluating the potential of t cell receptor repertoires in predicting the prognosis of resectable non-small cell lung cancers. Mol Ther Methods Clin Dev. 18:73–83. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Xu Y, Zhao M, Liu Y, Gong M, Xie C, Wu H and Wang Z: High-throughput T cell receptor sequencing reveals distinct repertoires between tumor and adjacent non-tumor tissues in HBV-associated HCC. Oncoimmunology. 5:e12190102016. View Article : Google Scholar : PubMed/NCBI | |
|
Lin KR, Deng FW, Jin YB, Chen XP, Pan YM, Cui JH, You ZX, Chen HW and Luo W: T cell receptor repertoire profiling predicts the prognosis of HBV-associated hepatocellular carcinoma. Cancer Med. 7:3755–3762. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D, Schirmacher P, et al: Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother. 62:1453–1461. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J, Sun G, Zhu P, Liu S, Ou M, Chen Z, Zou C, Chan FL, Dai Y and Sui W: Determination of the complexity and diversity of the TCR β-chain CDR3 repertoire in bladder cancer using high-throughput sequencing. Oncol Lett. 17:3808–3816. 2019.PubMed/NCBI | |
|
Zhang J, Wang Y, Huang Y, Tan X, Xu J, Yan Q, Tan J, Zhang Y, Zhang J, Ma Q, et al: Characterization of T cell receptor repertoire in penile cancer. Cancer Immunol Immunother. 73:242024. View Article : Google Scholar : PubMed/NCBI | |
|
Wang T, Wang C, Wu J, He C, Zhang W, Liu J, Zhang R, Lv Y, Li Y, Zeng X, et al: The different T-cell receptor repertoires in breast cancer tumors, draining lymph nodes, and adjacent tissues. Cancer Immunol Res. 5:148–156. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Zhang C, Pan Y, Xu R, Xu C, Chen Z, Lu Z and Ke Y: T cell receptor β-chain repertoire analysis reveals intratumour heterogeneity of tumour-infiltrating lymphocytes in oesophageal squamous cell carcinoma. J Pathol. 239:450–458. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 348:124–128. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M and Fong L: Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 6:238ra702014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Y, Zhao F, Li Z and Yu J: Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. Cancer Manag Res. 10:2475–2488. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ji S, Li J, Chang L, Zhao C, Jia R, Tan Z, Liu R, Zhang Y, Li Y, Yin G, et al: Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor. Clin Transl Oncol. 23:1646–1656. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, et al: Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 9:eaah35602017. View Article : Google Scholar : PubMed/NCBI | |
|
Kato T, Kiyotani K, Tomiyama E, Koh Y, Matsushita M, Hayashi Y, Nakano K, Ishizuya Y, Wang C, Hatano K, et al: Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. Oncoimmunology. 10:18629482021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu YY, Yang QF, Yang JS, Cao RB, Liang JY, Liu YT, Zeng YL, Chen S, Xia XF, Zhang K and Liu L: Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer. Int J Cancer. 145:1423–1431. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YT, Hsu HC, Lee YS, Liu H, Tan BC, Chin CY, Chang IY and Yang CY: Longitudinal high-throughput sequencing of the T-cell receptor repertoire reveals dynamic change and prognostic significance of peripheral blood TCR diversity in metastatic colorectal cancer during chemotherapy. Front Immunol. 12:7434482022. View Article : Google Scholar : PubMed/NCBI | |
|
Sheikh N, Cham J, Zhang L, DeVries T, Letarte S, Pufnock J, Hamm D, Trager J and Fong L: Clonotypic diversification of intratumoral T cells following sipuleucel-T treatment in prostate cancer subjects. Cancer Res. 76:3711–3718. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Frankowska K, Zarobkiewicz M, Dąbrowska I and Bojarska-Junak A: Tumor infiltrating lymphocytes and radiological picture of the tumor. Med Oncol. 40:1762023. View Article : Google Scholar : PubMed/NCBI | |
|
Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H and Falak R: Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Front Immunol. 13:10189622022. View Article : Google Scholar : PubMed/NCBI | |
|
Whiteside TL: Tumor-infiltrating lymphocytes and their role in solid tumor progression. Exp Suppl. 113:89–106. 2022.PubMed/NCBI | |
|
Giraldo NA, Becht E, Remark R, Damotte D, Sautès-Fridman C and Fridman WH: The immune contexture of primary and metastatic human tumours. Curr Opin Immunol. 27:8–15. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Akiyoshi T, Gotoh O, Tanaka N, Kiyotani K, Yamamoto N, Ueno M, Fukunaga Y and Mori S: T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer. Cancer Immunol Immunother. 70:509–518. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ge H, Ferris RL and Wang JH: Cetuximab responses in patients with HNSCC correlate to clonal expansion feature of peripheral and tumor-infiltrating T cells with top T-cell receptor clonotypes. Clin Cancer Res. 29:647–658. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Liu XS and Mardis ER: Applications of immunogenomics to cancer. Cell. 168:600–612. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER and Jaffee EM: T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI Insight. 3:e1220922018. View Article : Google Scholar : PubMed/NCBI | |
|
Postow MA, Manuel M, Wong P, Yuan J, Dong Z, Liu C, Perez S, Tanneau I, Noel M, Courtier A, et al: Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunother Cancer. 3:232015. View Article : Google Scholar : PubMed/NCBI | |
|
Arakawa A, Vollmer S, Tietze J, Galinski A, Heppt MV, Bürdek M, Berking C and Prinz JC: Clonality of CD4+ blood T cells predicts longer survival with CTLA4 or PD-1 checkpoint inhibition in advanced melanoma. Front Immunol. 10:13362019. View Article : Google Scholar : PubMed/NCBI | |
|
Han J, Duan J, Bai H, Wang Y, Wan R, Wang X, Chen S, Tian Y, Wang D, Fei K, et al: TCR repertoire diversity of peripheral PD-1+CD8+ T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer. Cancer Immunol Res. 8:146–154. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dong N, Moreno-Manuel A, Calabuig-Fariñas S, Gallach S, Zhang F, Blasco A, Aparisi F, Meri-Abad M, Guijarro R, Sirera R, et al: Characterization of circulating T cell receptor repertoire provides information about clinical outcome after PD-1 blockade in advanced non-small cell lung cancer patients. Cancers (Basel). 13:29502021. View Article : Google Scholar : PubMed/NCBI | |
|
Joshi K, Milighetti M and Chain BM: Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy. Curr Opin Immunol. 74:1–8. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
McGranahan N and Swanton C: Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell. 168:613–628. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback E, et al: Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 16:565–570. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, et al: Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 51:202–206. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, et al: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al: Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, et al: PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 386:2363–2376. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
O'Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, Bulat I, Meniawy TM, Bagameri A, Wang EW, et al: Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: An open-label phase II study. J Clin Oncol. 40:762–771. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Feng J, Gu T, Wang L, Wang Y, Zhou L, Hong R, Tan Su Yin E, Zhang M, Lu P and Huang H: CAR T-cell therapies in China: Rapid evolution and a bright future. Lancet Haematol. 9:e930–e941. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Grosser R, Cherkassky L, Chintala N and Adusumilli PS: Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 36:471–482. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pothuri VS, Hogg GD, Conant L, Borcherding N, James CA, Mudd J, Williams G, Seo YD, Hawkins WG, Pillarisetty VG, et al: Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma. Oncoimmunology. 13:23204112024. View Article : Google Scholar : PubMed/NCBI | |
|
Choudhury NJ, Kiyotani K, Yap KL, Campanile A, Antic T, Yew PY, Steinberg G, Park JH, Nakamura Y and O'Donnell PH: Low T-cell receptor diversity, high somatic mutation burden, and high neoantigen load as predictors of clinical outcome in muscle-invasive bladder cancer. Eur Urol Focus. 2:445–452. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jin YB, Luo W, Zhang GY, Lin KR, Cui JH, Chen XP, Pan YM, Mao XF, Tang J and Wang YJ: TCR repertoire profiling of tumors, adjacent normal tissues, and peripheral blood predicts survival in nasopharyngeal carcinoma. Cancer Immunol Immunother. 67:1719–1730. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Valpione S, Mundra PA, Galvani E, Campana LG, Lorigan P, De Rosa F, Gupta A, Weightman J, Mills S, Dhomen N and Marais R: The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat Commun. 12:40982021. View Article : Google Scholar : PubMed/NCBI | |
|
Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, et al: Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 11:6032020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Liu SYM, Chen Y, Ou Q, Bao H, Xu L, Zhang Y, Zhong W, Zhou Q, Yang XN, et al: Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial. JCI Insight. 7:e1526312022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Bie Z, Zhang Y, Li L, Zhu Y, Zhang Y, Nie X, Zhang P, Cheng G, Di X, et al: Prognostic value of the baseline circulating T cell receptor β chain diversity in advanced lung cancer. Oncoimmunology. 10:18996092021. View Article : Google Scholar : PubMed/NCBI | |
|
Abed A, Beasley AB, Reid AL, Law N, Calapre L, Millward M, Lo J and Gray ES: Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy. ESMO Open. 8:1020662023. View Article : Google Scholar : PubMed/NCBI | |
|
Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, et al: Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. OncoImmunology. 1:432–440. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yan C, Ma X, Guo Z, Wei X, Han D, Zhang T, Chen X, Cao F, Dong J, Zhao G, et al: Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. Oncoimmunology. 11:20256682022. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JW, Kim S, Yang SY, Joung JG and Hwang S: T-cell receptor repertoire characteristics associated with prognostic significance in high-grade serous ovarian carcinoma. Genes (Basel). 14:7852023. View Article : Google Scholar : PubMed/NCBI | |
|
Benítez R, Yu K, Sirota M, Malats N and Pineda S: Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer. Front Immunol. 14:9865982023. View Article : Google Scholar : PubMed/NCBI | |
|
Lecuelle J, Boidot R, Mananet H, Derangère V, Albuisson J, Goussot V, Arnould L, Tharin Z, Ray Coquard I, Ghiringhelli F, et al: TCR clonality and genomic instability signatures as prognostic biomarkers in high grade serous ovarian cancer. Cancers (Basel). 13:43942021. View Article : Google Scholar : PubMed/NCBI | |
|
Pan M and Li B: T cell receptor convergence is an indicator of antigen-specific T cell response in cancer immunotherapies. Elife. 11:e819522022. View Article : Google Scholar : PubMed/NCBI | |
|
Aran A, Garrigós L, Curigliano G, Cortés J and Martí M: Evaluation of the TCR repertoire as a predictive and prognostic biomarker in cancer: Diversity or clonality? Cancers (Basel). 14:17712022. View Article : Google Scholar : PubMed/NCBI | |
|
Attaf M, Huseby E and Sewell AK: αβ T cell receptors as predictors of health and disease. Cell Mol Immunol. 12:391–399. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nishida J, Cristea S, Bodapati S, Puleo J, Bai G, Patel A, Hughes M, Snow C, Borges V, Ruddy KJ, et al: Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression. Proc Natl Acad Sci USA. 120:e23167631202023. View Article : Google Scholar : PubMed/NCBI | |
|
Hiam-Galvez KJ, Allen BM and Spitzer MH: Systemic immunity in cancer. Nat Rev Cancer. 21:345–359. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Flumens D, Gielis S, Bartholomeus E, Campillo-Davo D, van der Heijden S, Versteven M, De Reu H, Smits E, Ogunjimi B, Laukens K, et al: Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells. Methods Cell Biol. 183:143–160. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SY, Liu CJ, Zhang Q and Guo AY: An ultra-sensitive T-cell receptor detection method for TCR-Seq and RNA-Seq data. Bioinformatics. 36:4255–4262. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Benotmane JK, Kueckelhaus J, Will P, Zhang J, Ravi VM, Joseph K, Sankowski R, Beck J, Lee-Chang C, Schnell O and Heiland DH: High-sensitive spatially resolved T cell receptor sequencing with SPTCR-seq. Nat Commun. 14:74322023. View Article : Google Scholar : PubMed/NCBI | |
|
Baker AM, Nageswaran G, Nenclares P, Ronel T, Smith K, Kimberley C, Laclé MM, Bhide S, Harrington KJ, Melcher A, et al: FUME-TCRseq enables sensitive and accurate sequencing of the T-cell receptor from limited input of degraded RNA. Cancer Res. 84:1560–1569. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Park JH and Lee HK: Function of γδ T cells in tumor immunology and their application to cancer therapy. Exp Mol Med. 53:318–327. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Eltoum IEA, Guo B, Beck BH, Cloud GA and Lopez RD: Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol. 180:6044–6053. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
He W, Hao J, Dong S, Gao Y, Tao J, Chi H, Flavell R, O'Brien RL, Born WK, Craft J, et al: Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin. J Immunol. 185:126–133. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chauvin C, Joalland N, Perroteau J, Jarry U, Lafrance L, Willem C, Retière C, Oliver L, Gratas C, Gautreau-Rolland L, et al: NKG2D controls natural reactivity of Vγ9Vδ2 T lymphocytes against mesenchymal glioblastoma cells. Clin Cancer Res. 25:7218–7228. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hao Q, Li R, Li H, Rui S, You L, Zhang L, Zhao Y, Li P, Li Y, Kong X, et al: Dynamics of the Γδtcr repertoires during the dedifferentiation process and pilot implications for immunotherapy of thyroid cancer. Adv Sci (Weinh). 11:e23063642024. View Article : Google Scholar : PubMed/NCBI |
